These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25843016)

  • 1. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.
    Smyth L; Browne PV; Conneally E; Flynn C; Hayden P; Jeffers M; O'Brien D; Quinn F; Kelly J; Perera M; Crotty GM; Leahy M; Hennessy B; Jackson F; Ryan M; Vandenberghe E
    Ir J Med Sci; 2016 Nov; 185(4):773-777. PubMed ID: 25843016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
    Sun H; Savage KJ; Karsan A; Slack GW; Gascoyne RD; Toze CL; Sehn LH; Abou Mourad Y; Barnett MJ; Broady RC; Connors JM; Forrest DL; Gerrie AS; Hogge DE; Narayanan S; Nevill TJ; Nantel SH; Power MM; Sutherland HJ; Villa D; Shepherd JD; Song KW
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):341-8. PubMed ID: 25656914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
    Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
    Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
    Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
    Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
    Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
    Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
    Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
    Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
    Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
    AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.
    Della Rocca AM; Leonart LP; Ferreira VL; Tonin FS; Steffenello-Durigon G; Del Moral JAG; Fernandez-Llimos F; Pontarolo R
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):514-525. PubMed ID: 33947633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.
    Rodrigo JA; Hicks LK; Cheung MC; Song KW; Ezzat H; Leger CS; Boro J; Montaner JS; Harris M; Leitch HA
    Adv Hematol; 2012; 2012():735392. PubMed ID: 22190945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
    Choi MK; Jun HJ; Lee SY; Kim KH; Lim DH; Kim K; Ko YH; Kim WS; Kim SJ
    Ann Hematol; 2009 Nov; 88(11):1099-106. PubMed ID: 19288103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
    Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
    Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire.
    Koffi GK; Tolo A; Nanho DC; N'dathz E; Kouassi MY; N'Diaye FD; Kouakou B; Meité N; Ayemou R; Sekongo M; Kouehion P; Meité M; Tea ND; Sangaré A; Sanogo I
    Int J Hematol; 2010 Jun; 91(5):838-43. PubMed ID: 20480270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.